Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia
Public ClinicalTrials.gov record NCT01009060. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomised Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Cognitive Enhancing Effect of GSK239512 in Stable Patients With Schizophrenia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study aims to evaluate the cognitive enhancing effects and tolerability of GSK239512 compared to placebo in patients with schizophrenia
Study identification
- NCT ID
- NCT01009060
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 50 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 1, 2009 (Actual)
- Primary completion
- Aug 10, 2011 (Actual)
- Completion
- Aug 10, 2011 (Actual)
- Last update posted
- Nov 8, 2017
2009 – 2011
United States locations
- U.S. sites
- 15
- U.S. states
- 8
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Garden Grove | California | 92845 | — |
| GSK Investigational Site | Los Angeles | California | 90073 | — |
| GSK Investigational Site | National City | California | 91950 | — |
| GSK Investigational Site | Sacramento | California | 95817 | — |
| GSK Investigational Site | San Diego | California | 92102 | — |
| GSK Investigational Site | Torrance | California | 90502 | — |
| GSK Investigational Site | Chicago | Illinois | 60611 | — |
| GSK Investigational Site | Indianapolis | Indiana | 46222 | — |
| GSK Investigational Site | Catonsville | Maryland | 21228 | — |
| GSK Investigational Site | Boston | Massachusetts | 02114 | — |
| GSK Investigational Site | Jamaica Plain | Massachusetts | 02130 | — |
| GSK Investigational Site | Mount Laurel | New Jersey | 08054 | — |
| GSK Investigational Site | New York | New York | 10016 | — |
| GSK Investigational Site | New York | New York | 10032 | — |
| GSK Investigational Site | Butner | North Carolina | 27509 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01009060, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 8, 2017 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01009060 live on ClinicalTrials.gov.